We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Celldex Therapeutics, Inc. (CLDX - Free Report) is expected to report third-quarter 2017 results next week. Its performance has been encouraging as it beat estimates in three of the trailing four quarters and met estimates in one, delivering an average positive surprise of 7.29%.
In the last reported quarter, the company delivered a positive earnings surprise of 8%.
Celldex Therapeutics’ shares are down 31.1% so far this year against a 3.3% increase registered by the industry during this period.
Let’s see how things are shaping up for this announcement.
Factors at Play
Celldex earns revenues entirely from product development and licensing agreements, and contracts and grants. The company recognizes revenues under its clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) for varlilumab. The company will continue to record revenues from these sources in the third quarter of 2017.
With no approved product in its portfolio, investor focus will remain on pipeline development.
Celldex’s most advanced pipeline candidate is glembatumumab vedotin, which is currently being evaluated for the treatment of triple negative breast cancer (phase IIb—METRIC study) and metastatic melanoma (phase II). Enrolment in the METRIC study closed this September, with data expected in the second quarter of 2018. In the melanoma study, Celldex added two new cohorts, a glembatumumab plus varlilumab arm (data expected in fall 2017) and a glembatumumab plus checkpoint inhibitor arm, including either Bristol Myers’ Opdivo or Merck’s Keytruda. In the melanoma study, glemba performed well in the single agent setting.
Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab, CDX-1401/CDX-301 (phase II—multiple solid tumors) and CDX-014 (phase I—advanced renal cell carcinoma) among others.
Varlilumab is being evaluated in combination with Opdivo in a phase II study that includes cohorts in five indications—colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, renal cell carcinoma and glioblastoma. Celldex plans to complete enrolment across all cohorts in the phase II portion of the study in the first quarter of 2018. Meanwhile, data from the phase I study of varlilumab/Opdivo combination study was presented in June. The study met its primary endpoint as the combination was well tolerated at all tested dose levels.
Though R&D and SG&A costs declined in the second quarter, operating expenses may vary on a quarterly basis.
Earnings Whispers
Our proven model does not conclusively show that Celldex is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 24 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Celldex’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +2.9% and a Zacks Rank #3. The company is scheduled to release results on Nov 7.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
Celldex Therapeutics, Inc. (CLDX - Free Report) is expected to report third-quarter 2017 results next week. Its performance has been encouraging as it beat estimates in three of the trailing four quarters and met estimates in one, delivering an average positive surprise of 7.29%.
In the last reported quarter, the company delivered a positive earnings surprise of 8%.
Celldex Therapeutics’ shares are down 31.1% so far this year against a 3.3% increase registered by the industry during this period.
Let’s see how things are shaping up for this announcement.
Factors at Play
Celldex earns revenues entirely from product development and licensing agreements, and contracts and grants. The company recognizes revenues under its clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) for varlilumab. The company will continue to record revenues from these sources in the third quarter of 2017.
With no approved product in its portfolio, investor focus will remain on pipeline development.
Celldex’s most advanced pipeline candidate is glembatumumab vedotin, which is currently being evaluated for the treatment of triple negative breast cancer (phase IIb—METRIC study) and metastatic melanoma (phase II). Enrolment in the METRIC study closed this September, with data expected in the second quarter of 2018. In the melanoma study, Celldex added two new cohorts, a glembatumumab plus varlilumab arm (data expected in fall 2017) and a glembatumumab plus checkpoint inhibitor arm, including either Bristol Myers’ Opdivo or Merck’s Keytruda. In the melanoma study, glemba performed well in the single agent setting.
Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab, CDX-1401/CDX-301 (phase II—multiple solid tumors) and CDX-014 (phase I—advanced renal cell carcinoma) among others.
Varlilumab is being evaluated in combination with Opdivo in a phase II study that includes cohorts in five indications—colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, renal cell carcinoma and glioblastoma. Celldex plans to complete enrolment across all cohorts in the phase II portion of the study in the first quarter of 2018. Meanwhile, data from the phase I study of varlilumab/Opdivo combination study was presented in June. The study met its primary endpoint as the combination was well tolerated at all tested dose levels.
Though R&D and SG&A costs declined in the second quarter, operating expenses may vary on a quarterly basis.
Earnings Whispers
Our proven model does not conclusively show that Celldex is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 24 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Celldex’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Celldex Therapeutics, Inc. Price and EPS Surprise
Celldex Therapeutics, Inc. Price and EPS Surprise | Celldex Therapeutics, Inc. Quote
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Clovis Oncology, Inc. is scheduled to release results on Nov 1 after market close. The company has an Earnings ESP of +2.01% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +2.9% and a Zacks Rank #3. The company is scheduled to release results on Nov 7.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>